Will HIV vaccines compete with existing HIV prevention strategies? Who is doing COVID vaccine cost-effectiveness analysis? Fred Hutch Science Spotlight translated the math in our peer-reviewed paper published in the Journal of the International AIDS Society to explain the economic tradeoffs of delivering an HIV vaccine in Seattle in the future. Our prior review of…
Category: HIV
Solid Machine Learning Model Predicts New HIV Cases Using EHR Data
Incredible new research from Harvard and Kaiser contributed two substantial leaps forward this summer: first in the useful application of machine learning predictions using electronic health records and second in the accurate targeting of people who can benefit the most from HIV pre-exposure prophylaxis. This paper in Lancet HIV by Marcus and colleagues is so good…
How to find acute HIV cases in a hot epidemic
One of the most highly infectious time periods in the life of a person with HIV is also when that person is most likely unaware of their HIV status. This is the acute stage. Shortly after infection, the virus explodes with a measurable peak in the number of copies floating around. This feature of the…
Age-based priority groups for efficient vaccination in South Africa
New paper in Vaccine shows staggered age targeting and the durability of protection will be key to strategic and efficient vaccination in South Africa. When an HIV vaccine is ready to launch in South Africa, an efficient implementation strategy needs to be ready. I worked with 3 women scientists in South Africa, 3 academic men…
How to replicate visualization of trajectory towards UNAIDS 90-90-90 goals
In this tutorial, you’ll gain access to the R code, dataset, and motivation to replicate data visualizations in my latest paper and apply the concepts to your next one. I sat on an airplane last year, flipping through The Economist, when I froze at the sight of a tiny chart littered with a mess of…
Should we pay some people to take their HIV drugs?
There is little prior evidence of effective interventions to improve viral suppression, despite this being a critical step in the HIV care continuum as described in the National HIV/AIDS Strategy for the United States.
Progress in viral suppression shifts distribution of metrics in US states
While preparing a review for the journal Current HIV/AIDS Reports, I uncovered some interesting longitudinal trends in the care cascade and heterogeneity in the progress of US states. The following visualizations describe CDC HIV surveillance data from 2010-2014. They didn’t make the cut for our review paper, and they are too beautiful and interesting to…
Defended
On Thursday, May 3, 2018, I defended my doctoral dissertation research in The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington and became a doctor. Mathematical Models Interrogation The priviledge to ask and answer my own scientific questions was only possible because of the dedicated professors and mentors who gifted…
Investment Round
Lab coats are being ironed, promo stickers wrapped around candy bars, and strangers pulled off the street to help with utility testing. It’s time for the Business Plan Competition.
BBC Interview
On Tuesday, April 17, the journal Nature Scientific Reports published our paper “Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.” A few hours later, a reporter from BBC World Service reached out to discuss the the results of our study. Live Interview You can listen to this clip with…